FDA Delves Into Broader Smoking Cessation Approach
This article was originally published in The Tan Sheet
FDA’s questions for comments in a notice for a public hearing on smoking cessation approaches suggest a willingness to take an expanded approach to nicotine replacement therapy approvals and indications. Discussion topics include fast-track and accelerated approval authorities for NRTs and extended use of the products.
You may also be interested in...
CN Creative’s plan to include harm reduction with smoking cessation in claims for its Nicadex electronic cigarette was key to Advent Life Sciences investing in the firm, which is prepared to ask U.K. regulators for approval this summer before applying in the U.S.
Speakers at a workshop on nicotine-replacement therapy point abroad for guidance on expanding indications for smoking-cessation products as an FDA official says the agency likely will put the question before an advisory committee.
FDA's stated commitment to a public health approach to drug regulation will be put to the test by a petition to expand nicotine replacement therapy indications and availability